This article covers healthcare communications strategy in the UAE only: the difference between regulated advertising and earned media coverage. It contains no medical information, treatment guidance or clinical claims, and nothing here should be read as such. Anyone with a health question should consult a licensed medical professional. This is not legal or regulatory advice; a health brand's own compliance and legal counsel should confirm current requirements before any public claim is made.
The core distinction: advertising versus PR
Healthcare advertising is paid promotion, and it's directly regulated in the UAE: the Dubai Health Authority (DHA) and the Ministry of Health and Prevention (MOHAP) require pre-approval for advertisements and promotional content, particularly anything containing treatment claims, pricing, or comparisons with other providers. Healthcare PR is earned editorial coverage, a journalist choosing to cover a genuinely newsworthy story, rather than a paid placement. The two are legally and practically distinct, and confusing them is a real risk for any health brand communicating publicly in the UAE.
Why this distinction matters practically
A health brand might reasonably assume that earned coverage sits outside advertising regulation entirely, since no payment changes hands. That's broadly true procedurally, but it doesn't create an exception for the underlying content standard. A claim that would need DHA/MOHAP pre-approval if made in a paid advertisement should be held to the same substantiation standard even when it appears in earned coverage, rather than treated as a loophole around the approval process.
What publicly available guidance suggests about restricted claims
Based on the public regulatory framework: no cure or treatment-outcome claims without clinical evidence meeting DHA's evidentiary standards, no comparative claims against other providers without documented substantiation, and no testimonials implying guaranteed outcomes. This applies most strictly to advertising, but the same discipline should guide anything a health brand says publicly, including in press interviews or bylined commentary.
What genuinely newsworthy healthcare stories look like
Stories a health or healthtech brand can speak to without making a clinical claim: a new facility or service opening, a healthtech product launch (described by what it does, not by clinical outcomes it hasn't demonstrated through proper evidence), leadership appointments, and expert commentary from clinicians or executives on trends and policy in UAE healthcare. The story has to be genuinely newsworthy on its own merits, not a promotional claim dressed up as news to route around the advertising approval process.
Typical approval timelines
Publicly available guidance suggests roughly two to four weeks for standard advertising campaigns, though this varies by submission type and should be confirmed directly with DHA/MOHAP or a client's regulatory counsel for a specific case. This isn't something a PR or communications team can shortcut, and it's worth building into a launch timeline from the start rather than treating it as a late-stage formality.
A practical approach for health and healthtech brands
Scope every public statement against the question: does this claim need DHA/MOHAP pre-approval if made in an advertisement, and if so, is it substantiated to that standard even though it's appearing as earned coverage rather than a paid placement. When in doubt, involve compliance and legal counsel before publication, not after. See our full approach to healthcare communications in the UAE for how this scope-first discipline applies across a full PR programme.